

ISO 14155:2026-03 (E)

Clinical investigation of medical devices for human subjects - Good clinical practice

Contents

Page

Foreword.....	vi
Introduction.....	viii
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions.....	1
4 Summary of good clinical practice principles.....	9
5 Ethical considerations.....	10
5.1 General.....	10
5.2 Improper influence or inducement.....	10
5.3 Compensation and additional health care.....	10
5.4 Registration in publicly accessible database.....	11
5.5 Responsibilities.....	11
5.6 Communication with the ethics committee.....	11
5.6.1 General.....	11
5.6.2 Initial EC submission.....	11
5.6.3 Information to be obtained from the EC.....	12
5.6.4 Continuing communication with the EC.....	12
5.6.5 Continuing information to be obtained from the EC.....	12
5.7 Vulnerable populations.....	12
5.8 Informed consent.....	13
5.8.1 General.....	13
5.8.2 Process of obtaining informed consent.....	13
5.8.3 Special circumstances for informed consent.....	14
5.8.4 Information to be provided to the subject.....	15
5.8.5 Informed consent signature.....	16
5.8.6 New information.....	17
6 Clinical investigation planning.....	17
6.1 General.....	17
6.2 Risk management.....	17
6.2.1 General.....	17
6.2.2 Risks related to the use of the investigational device and their disclosure.....	18
6.2.3 Risks related to clinical procedures required by the CIP outside routine clinical practice.....	18
6.2.4 Risks related to the clinical investigation process.....	19
6.3 Justification for the design of the clinical investigation.....	19
6.4 Clinical investigation plan.....	19
6.5 Investigator's brochure.....	20
6.6 Case report forms.....	20
6.7 Monitoring plan.....	20
6.8 Investigation site selection.....	21
6.9 Agreement(s).....	22
6.10 Labelling.....	22
6.11 Data monitoring committee.....	22
6.12 Clinical events committee.....	22
7 Clinical investigation conduct.....	23
7.1 General.....	23
7.2 Investigation site initiation.....	23

7.3	Investigation site monitoring.....	23
7.4	Adverse events and device deficiencies.....	23
7.4.1	Signals requiring immediate action.....	23
7.4.2	Adverse events.....	23
7.4.3	Device deficiencies.....	24
7.4.4	Risk assessment process for potentially unacceptable risks related to the use of the investigational device.....	24
7.4.5	Management of risks related to clinical procedures required by the CIP outside routine clinical practice.....	25
7.5	Clinical investigation documents and documentation.....	25
7.5.1	Amendments.....	25
7.5.2	Subject identification log.....	25
7.5.3	Source documents.....	26
7.6	Additional members of the investigation site team.....	26
7.7	Subject privacy and confidentiality of data.....	26
7.8	Document and data control.....	26
7.8.1	Traceability of documents and data.....	26
7.8.2	Recording of data.....	26
7.8.3	Electronic clinical data systems.....	27
7.9	Investigational device accountability.....	28
7.10	Accounting for subjects.....	28
7.11	Auditing.....	28
8	Suspension, termination and close-out of the clinical investigation.....	29
8.1	Completion of the clinical investigation.....	29
8.2	Suspension or premature termination of the clinical investigation.....	29
8.2.1	General.....	29
8.2.2	Procedure for suspension.....	29
8.2.3	Procedure for premature termination.....	30
8.2.4	Procedure for resuming the clinical investigation after suspension.....	30
8.3	Routine close-out.....	31
8.4	Clinical investigation report.....	31
8.5	Risk assessment and conclusions.....	32
8.6	Document retention.....	32
9	Responsibilities of the sponsor.....	32
9.1	Clinical quality management.....	32
9.2	Clinical investigation planning and conduct.....	33
9.2.1	Selection and training of clinical personnel.....	33
9.2.2	Preparation of documents and materials.....	34
9.2.3	Conduct of clinical investigation.....	34
9.2.4	Monitoring.....	35
9.2.5	Safety evaluation and reporting.....	37
9.2.6	Clinical investigation close-out.....	38
9.3	Outsourcing of duties and functions.....	38
9.4	Communication with regulatory authorities.....	39
10	Responsibilities of the principal investigator.....	39
10.1	General.....	39
10.2	Qualification of the principal investigator.....	39
10.3	Qualification of investigation site.....	39
10.4	Communication with the EC.....	40
10.5	Informed consent process.....	40
10.6	Compliance with the CIP.....	40
10.7	Medical care of subjects.....	41
10.8	Safety reporting.....	42
	Annex A (normative) Clinical investigation plan.....	43
	Annex B (normative) Investigator's brochure.....	51
	Annex C (informative) Case report forms.....	54
	Annex D (normative) Clinical investigation report.....	56
	Annex E (informative) Essential clinical investigation documents.....	61
	- 2 - Annex F (informative) Adverse event categorization.....	67

Annex G (informative) EC responsibilities..... 69
Annex H (informative) Application of ISO 14971 during clinical investigations..... 73
Annex I (informative) Clinical development stages 74
Annex J (informative) Clinical investigation audits 79
Annex K (informative) Clinical investigation design considerations..... 82
Bibliography..... 84